US83175M2052 - SNN - 939163 (XNYS)
SMITH+NEPHEW ADR5 DL-20/2 Certificado de depósito
24,43 USD
Cotizaciones actuales de SMITH+NEPHEW ADR5 DL-20/2
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria | Variación diaria % |
---|---|---|---|---|---|---|
NYSE |
SNN
|
USD
|
24.12.2024 19:00
|
24,43 USD
| 24,53 USD | -0,41 % |
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
0,00 % | -1,85 % | -3,36 % | -20,14 % | -2,71 % | -10,45 % | -49,02 % |
Company Profile for SMITH+NEPHEW ADR5 DL-20/2 Depository Receipt
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Company Data SMITH+NEPHEW ADR5 DL-20/2 Depository Receipt
Name SMITH+NEPHEW ADR5 DL-20/2
Company Smith & Nephew plc
Symbol SNN
Website https://www.smith-nephew.com
Primary Exchange
NYSE
WKN 939163
ISIN US83175M2052
Asset Class Depository Receipt
Sector Healthcare
Industry Medical - Devices
CEO Dr. Deepak S. Nath Ph.D.
Market Capitalization 13 Mrd.
Country United Kingdom
Currency USD
Employees 18,0 T
Address Building 5, WD18 8YE Watford
IPO Date 1999-11-16
Stock Splits
Date | Split |
---|---|
15.10.2014 | 2499:1000 |
16.12.2003 | 2:1 |
07.08.2000 | 9:11 |
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | NPWA.F |
NYSE | SNN |
More Shares
Investors who SMITH+NEPHEW ADR5 DL-20/2 hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.